Home / Market News / $PLSE

$PLSE news and market catalysts

The 16 most recent market catalysts affecting $PLSE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

16 catalysts 2 high impact 9 bullish 3 bearish Medical Devices
Nov 6, 2026 Corporate Catalyst Bullish Impact 75
Pulse Biosciences Presents Six-Month Interim Results from PRECISE-BTN Study
Pulse Biosciences (PLSE) has released highly encouraging six-month interim results from its PRECISE-BTN study, demonstrating an 86% patient response rate with significant thyroid n…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Needham Raises Price Target on Pulse Biosciences to $64
Needham & Co. raised its price target on Pulse Biosciences (PLSE) to $64 from $58, maintaining a Buy rating, after reviewing the company's recent business updates and Q3 2026 finan…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Pulse Biosciences reported its Q3 2026 financial results and, more importantly, announced the completion of enrollment in its U.S. pivotal IDE study three months ahead of its origi…
Oct 14, 2026 Corporate Catalyst Bullish Impact 65
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Pulse Biosciences has partnered with the Clayman Thyroid Center, a prominent institution, for both commercial deployment and clinical data generation of its nPulse Vybrance System.…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia has maintained an 'Outperform' rating on Pulse Biosciences (PLSE) and raised the price target from $35 to $60. This is a significant positive signal…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58
Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on Pulse Biosciences and significantly raised the price target from $43 to $58. This action signals increased c…
Sep 23, 2026 Corporate Catalyst Neutral Impact 65
BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70
BTIG's initiation of coverage on Pulse Biosciences with a 'Buy' rating and a $70 price target is a positive development for the company. Analyst coverage often brings increased vis…
Sep 15, 2026 Corporate Catalyst Bullish Impact 65
Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates its nPulse Vybrance Percutaneous Electrode System for symptomatic benig…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Pulse Biosciences shares are trading higher after Freedom Capital Markets initiated coverage on the stock with a Buy rating and announced a $73 price target.
The initiation of coverage with a 'Buy' rating and a substantial price target from a financial institution like Freedom Capital Markets is a strong positive catalyst for Pulse Bios…
Sep 9, 2026 Corporate Catalyst Neutral Impact 65
Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73
Freedom Capital Markets analyst Keith Hinton has initiated coverage on Pulse Biosciences (PLSE) with a 'Buy' rating and a $73 price target. This event is significant because new an…
Aug 17, 2026 Corporate Catalyst Neutral Impact 65
Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58
Needham's initiation of coverage on Pulse Biosciences with a 'Buy' rating and a $58 price target is a positive development for the company. Analyst coverage can increase visibility…
Aug 10, 2026 Corporate Catalyst Bullish Impact 65
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43
Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on Pulse Biosciences and raised the price target from $32 to $43. This analyst upgrade suggests increased confi…
Aug 7, 2026 Corporate Catalyst Bearish Impact 75
Pulse Biosciences shares are trading higher after the company reported Q2 financial results. The stock initially fell yesterday after the market closed, but it has since reversed.
This headline indicates a strong corporate catalyst for Pulse Biosciences. The initial dip after hours, followed by a significant reversal, suggests that investors may have initial…
Aug 6, 2026 Corporate Catalyst Bearish Impact 85
Pulse Biosciences shares are trading lower after the company reported worse-than-expected Q2 sales results.
This headline represents a significant corporate catalyst directly impacting Pulse Biosciences. Worse-than-expected sales results often lead to immediate negative investor sentimen…
Aug 6, 2026 Corporate Catalyst Bearish Impact 85
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate
Pulse Biosciences announced Q2 earnings where EPS of $(0.36) met analyst consensus, but sales of $434,000 missed estimates by 18.62%. This is a significant revenue miss, suggesting…
Jul 29, 2026 Corporate Catalyst Bullish Impact 75
Pulse Biosciences Says NANOPULSE-AF Atrial Fibrillation Study Surpasses Enrollment Midpoint After April 2026 Start; Update Due On August 6 Earnings Call
This headline is a significant corporate catalyst for Pulse Biosciences (PLSE). Surpassing the enrollment midpoint for a pivotal clinical trial, especially ahead of a relatively re…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.